BDNF plasma levels variations in major depressed patients receiving duloxetine

Neurological Sciences

Volumn 36, Issue 5, 2015, Pages 729-734

  Fornaro, Michele ^a,b   Escelsior, Andrea ^a   Rocchi, Giulio ^a   Conio, Benedetta ^a   Magioncalda, Paola ^a   Marozzi, Valentina ^a   Presta, Andrea ^a   Sterlini, Bruno ^c   Contini, Paola ^a   Amore, Mario ^a   Fornaro, Pantaleo ^a   Martino, Matteo ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

BDNF; Depression; Duloxetine; Neuroendocrine immunity; Neuroplasticity

Indexed keywords

ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; DULOXETINE;

ADOLESCENT; ADULT; AGED; BLOOD; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMAN; MALE; MIDDLE AGED; OUTPATIENT; PSYCHOLOGICAL RATING SCALE; TIME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSIVE DISORDER, MAJOR; DULOXETINE HYDROCHLORIDE; FEMALE; HUMANS; MALE; MIDDLE AGED; OUTPATIENTS; PSYCHIATRIC STATUS RATING SCALES; TIME FACTORS; YOUNG ADULT;

EID: 84939940786     PISSN: 15901874     EISSN: 15903478     Source Type: Journal    
DOI: 10.1007/s10072-014-2027-7     Document Type: Article

References (23)

1. Sen S, Duman R, Sanacora G (2008) Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 64(6):527–532. doi:10.1016/j.biopsych.2008.05.005
2. Brunoni AR, Lopes M, Fregni F (2008) A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 11(8):1169–1180. doi:10.1017/S1461145708009309
3. Debonnel G, Saint-Andre E, Hebert C, de Montigny C, Lavoie N, Blier P (2007) Differential physiological effects of a low dose and high doses of venlafaxine in major depression. Int J Neuropsychopharmacol 10(1):51–61. doi:10.1017/S1461145705006413
4. Martino M, Rocchi G, Escelsior A, Fornaro M (2012) Immunomodulation mechanism of antidepressants: interactions between serotonin/norepinephrine balance and Th1/Th2 balance. Curr Neuropharmacol 10 [ahead of print]
5. Lee HY, Kim YK (2008) Plasma brain-derived neurotrophic factor as a peripheral marker for the action mechanism of antidepressants. Neuropsychobiology 57(4):194–199. doi:10.1159/000149817
6. Rojas PS, Fritsch R, Rojas RA, Jara P, Fiedler JL (2011) Serum brain-derived neurotrophic factor and glucocorticoid receptor levels in lymphocytes as markers of antidepressant response in major depressive patients: a pilot study. Psychiatry Res 189(2):239–245. doi:10.1016/j.psychres.2011.04.032
7. Basterzi AD, Yazici K, Aslan E, Delialioglu N, Tasdelen B, Tot Acar S, Yazici A (2009) Effects of fluoxetine and venlafaxine on serum brain derived neurotrophic factor levels in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 33(2):281–285. doi:10.1016/j.pnpbp.2008.11.016
8. Matrisciano F, Bonaccorso S, Ricciardi A, Scaccianoce S, Panaccione I, Wang L, Ruberto A, Tatarelli R, Nicoletti F, Girardi P, Shelton RC (2009) Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine. J Psychiatr Res 43(3):247–254. doi:10.1016/j.jpsychires.2008.03.014
9. Lee BH, Myint AM, Kim YK (2010) Psychotropic drugs on in vitro brain-derived neurotrophic factor production in whole blood cell cultures from healthy subjects. J Clin Psychopharmacol 30(5):623–627. doi:10.1097/JCP.0b013e3181f13f0b
10. Martinowich K, Lu B (2008) Interaction between BDNF and serotonin: role in mood disorders. Neuropsychopharmacology 33(1):73–83. doi:10.1038/sj.npp.1301571
11. Tardito D, Perez J, Tiraboschi E, Musazzi L, Racagni G, Popoli M (2006) Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic mechanisms in the action of antidepressants: a critical overview. Pharmacol Rev 58(1):115–134. doi:10.1124/pr.58.1.7
12. Ball S, Marangell LB, Lipsius S, Russell JM (2013) Brain-derived neurotrophic factor in generalized anxiety disorder: results from a duloxetine clinical trial. Prog Neuropsychopharmacol Biol Psychiatry. doi:10.1016/j.pnpbp.2013.01.002
13. Trivedi MH, Desaiah D, Ossanna MJ, Pritchett YL, Brannan SK, Detke MJ (2008) Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine. Int Clin Psychopharmacol 23(3):161–169. doi:10.1097/YIC.0b013e3282f41d7e
14. APA (1994) Diagnostic and statistical manual for mental disorders, 4th edn. American Psychiatrich Association, Washington
15. Ventura J, Liberman RP, Green MF, Shaner A, Mintz J (1998) Training and quality assurance with the Structured Clinical Interview for DSM-IV (SCID-I/P). Psychiatry Res 79(2):163–173 (S0165-1781(98)00038-9)
16. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62
17. Young RC, Biggs JT, Ziegler VE, Meyer DA (1978) A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 133:429–435
18. Fornaro M, Martino M, Battaglia F, Colicchio S, Perugi G (2011) Increase in IL-6 levels among major depressive disorder patients after a 6-week treatment with duloxetine 60 mg/day: a preliminary observation. Neuropsychiatr Dis Treat 7:51–56. doi:10.2147/NDT.S16382
19. Fornaro M, Bandini F, Ogliastro C, Cordano C, Martino M, Cestari L, Escelsior A, Rocchi G, Colicchio S, Perugi G (2011) Electroretinographic assessment in major depressed patients receiving duloxetine: might differences between responders and non-responders indicate a differential biological background? J Affect Disord 135(1–3):154–159. doi:10.1016/j.jad.2011.07.013
20. Fornaro M, Rocchi G, Escelsior A, Contini P, Martino M (2012) Might different cytokine trends in depressed patients receiving duloxetine indicate differential biological backgrounds. J Affect Disord. doi:10.1016/j.jad.2012.08.007
21. Martino M, Rocchi G, Escelsior A, Fornaro M (2012) Immunomodulation Mechanism of Antidepressants: interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance. Curr Neuropharmacol 10(2):97–123. doi:10.2174/157015912800604542
22. Cirulli F, Alleva E (2009) The NGF saga: from animal models of psychosocial stress to stress-related psychopathology. Front Neuroendocrinol 30(3):379–395. doi:10.1016/j.yfrne.2009.05.002
23. Hashimoto K (2010) Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatry Clin Neurosci 64(4):341–357. doi:10.1111/j.1440-1819.2010.02113.x